Results: One hundred and twenty-three patients received ≥1 cycle of therapy (63, 21-day regimen; 60, 28-day regimen). ORRs were 13% [95% confidence interval (CI) 6%-24%] and 17% (95% CI 8%-29%), and disease control rates were 48% (95% CI 35%-61%) and 63% (95% CI 50%-75%) for the 21-and 28-day regimens, respectively. The median progression-free survival and overall survival were similar with both regimens. Both regimens were well tolerated with common grade ≥3 toxicities being neutropenia, asthenia/fatigue, and dyspnoea. Sequential administration of erlotinib did not interfere with the pharmacokinetic profile of eribulin.
Early studies investigating concomitant administration of cytotoxic drugs and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) did not indicate synergism [8] [9] [10] [11] . However, recent evidence suggests that sequential administration, involving intermittent EGFR-TKI dosing intercalated between chemotherapy cycles, may improve treatment outcome [12] [13] [14] . A placebo-controlled, randomized phase II study of sequential administration of gemcitabine/platinum chemotherapy followed by 14 days' erlotinib or placebo as first-line treatment showed significant prolongation of progression-free survival (PFS) [12] .
The non-taxane microtubule dynamics inhibitor eribulin mesilate (International Non-proprietary Name eribulin) is indicated in the EU as monotherapy for the treatment of patients with advanced stage breast cancer who have progressed after at least two chemotherapeutic regimens. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments [15] . A phase II study of singleagent eribulin as second-line therapy for NSCLC reported an objective response rate (ORR) of 10% [16] . We postulated that an intercalated combination of eribulin and erlotinib would be efficacious in patients with advanced NSCLC and unknown EGFR mutation status.
Eribulin mesylate is administered on days 1 and 8 within every 21-day cycle. We modified this regimen to accommodate at least 14 days of erlotinib in the intercalated combination. The objective of this randomized phase II study was to evaluate the efficacy and tolerability of these two intercalated regimens of eribulin and erlotinib in patients with advanced NSCLC previously treated with platinum-based doublet chemotherapy.
patients and methods

study design
In this open-label, multicentre, phase II study, patients were randomized 
patients and study objectives
Key inclusion criteria were: 18 years or older; histologically confirmed NSCLC with measurable disease; ≥1 prior platinum-based doublet chemotherapy for recurrent/advanced NSCLC; disease progression during or after last anti-cancer therapy; Eastern Cooperative Oncology Group performance status ≤2; adequate bone marrow, liver, and renal function. Exclusion criteria included: prior therapy with eribulin or EGFR-TKI; known brain metastases unless treated and stable; and pre-existing neuropathy grade >2.
The primary efficacy end point was ORR. Secondary efficacy end points were PFS, duration of response (DOR), disease control rate (DCR), and OS. Clinical benefit rate (CBR) was an exploratory efficacy end point. Safety, pharmacokinetic (PK), and exploratory biomarker analyses were also carried out. assessments efficacy and safety. Tumour response was assessed by the investigator (with Response Evaluation Criteria in Solid Tumors [17] ) every 8 weeks or sooner if progressive disease (PD) was suspected. Complete responses (CRs) and partial responses (PRs) required confirmation by scanning after 4 weeks or more. DCR and CBR included CR, PR, or stable disease (SD; ≥7 weeks for DCR; ≥6 months for CBR). DOR was time from first documented evidence of response (CR or PR) until PD or death. PFS was time from randomization until date of PD or death. OS was time from randomization until death due to any cause, last date known alive, or study cut-off (censored).
Adverse events (AEs) and serious AEs (SAEs) were assessed according to the National Cancer Institute Common Terminology Criteria for AEs (version 4).
pharmacokinetics. Sampling was carried out for the first 12 subjects in each dose regimen enrolled at sites able to perform PK assessments. Blood samples were collected 5 min pre-dose, and 5 min, 0.25, 0.5, 1, 2, 4, 6-8, 24-26, 72-120, and 168 h after day 1 administration of eribulin in cycles 1 and 2. Plasma concentrations of eribulin were quantified by a validated liquid chromatographytandem mass spectrometry method [18] . PK parameters were estimated using non-compartmental analysis of plasma concentration-time data.
exploratory analyses: biomarker assessments. Archival tumour specimens (paraffin blocks or unstained slides) were sent to a central laboratory (Genzyme Genetics, now LabCorp Integrated Oncology). Formalinfixed, paraffin-embedded sections were analysed for EGFR expression by standard immunohistochemistry procedure and for EGFR gene amplification and/or high polysomy by fluorescence in situ hybridization using EGFR-CEP7® dual-colour DNA probe (Vysis®). Tumour DNA from tissue samples was analysed for KRAS mutation in codons 12 and 13 by single-nucleotide primer extension and for EGFR mutation by polymerase chain reaction amplification and bidirectional gene sequencing of exons 18-21 of the tyrosine kinase domain.
statistical analyses
For efficacy end points, primary analyses were based on the intent-to-treat population (all randomized patients). The safety population included all randomized patients who received at least one dose of study drug, and had at least one post-baseline safety evaluation. The PK population comprised all patients who received at least one dose of study drug and had evaluable PK data. Biomarker analyses were carried out on patients with evaluable biomarker samples.
Approximately 100 patients were to be randomized; however, according to a protocol amendment, enrolment of non-Asian patients was stopped and additional Asian patients were enrolled to allow for the recruitment of ≥30% Asian patients in order to enrol the requisite number of patients with EGFR mutation [19] . For each study arm, the 90% one-sided confidence interval (CI) would have 80% power to exclude the historical control ORR of 9% for erlotinib alone if the sample size was 50 patients and the ORR was 20% for the combination. The decision rule for this study was to identify a combination regimen with a potentially higher ORR than single-agent erlotinib; an observation of the ORR of 20% or above would imply a 90% confidence that there is potential synergy between the two agents. Data cut-off for the primary analysis occurred when the last patient completed the week 16 tumour assessment or was off-study.
The sample size was not powered for formal statistical treatment comparisons; both regimens were experimental. ORRs were computed with 90% one-sided and 95% two-sided CIs using the Clopper-Pearson method [20] . The median PFS, DOR, and OS were calculated with two-sided 95% CIs using the Kaplan-Meier method. For DCR and CBR, the corresponding exact Clopper-Pearson 95% two-sided CIs were computed. Safety data were summarized using descriptive statistics. Planned exploratory analyses evaluated the correlation between biomarkers and best ORR (Fisher's exact test; ORR 'Yes' defined as 'CR' or 'PR', ORR 'No' defined as 'SD' or 'PD'), PFS (Kaplan-Meier's curve, log-rank test), and reduction in tumour volume (Wilcoxon's test). CI, 8-29; one-sided P-value of 0.041 compared with the prespecified reference ORR of 9%) for the 28-day regimen (supplementary Table S1 , available at Annals of Oncology online).
The DCR was higher with the 28-day (63%) compared with the 21-day (48%) regimen, although the CBR was similar. The median DOR was 9.4 months (95% CI, 2.7-censored) for the 21-day regimen. The median DOR for the 28-day regimen was 9.7 months (95% CI 5.6-censored). The median PFS was 3.5 and 3.8 months, and the median OS 7.6 and 8.5 months for the 21-and 28-day regimen, respectively ( Figure 2A and B) .
safety. With both regimens, all patients reported AEs and the incidences of grade ≥3 AEs were 84% for the 21-day regimen and 80% for the 28-day regimen. The total number of deaths considered to be treatment-related was 5 (21-day: febrile neutropenia, acute respiratory failure, and pneumonia; 28-day: febrile neutropenia and pneumonia). Other AEs were mostly disease-related. The incidences of AEs (all grades) are summarized in supplementary Table S2 , available at Annals of Oncology online. Most common grade ≥3 AEs for the 21-and 28-day regimens included neutropenia (56% versus 48%), asthenia/fatigue (13% versus 12%), and dyspnoea (10% for both regimens). Febrile neutropenia original articles Annals of Oncology occurred in more patients on the 21-day regimen than the 28-day regimen (17% versus 5%). More patients on the 21-day regimen required dose reductions due to AEs (40% versus 27% for the 28-day regimen), and the incidence of SAEs also appeared to be higher (60% versus 45%), including a higher incidence of SAEs requiring/ prolonging hospitalization (59% versus 35%). More patients on the 21-day regimen experienced AEs leading to study drug withdrawal (24% versus 10% for the 28-day regimen). A total of 15 patients had AEs resulting in death.
pharmacokinetics. Eribulin PK parameters were similar to those defined previously [21] , and comparable between the 21-and 28-day dosing regimens (supplementary Table S3 , available at Annals of Oncology online). The mean elimination half-life in cycle 1 ranged from 27 to 32 h.
There was a dose-related increase in eribulin exposure: the mean area under the concentration-time curve (AUC) from time zero to infinity for cycle 1 was 851.5 and 1276.5 ng·h/ml following 1.4 and 2 mg/m 2 dose administration, respectively. Dose-normalized exposure was similar on day 1 of cycles 1 and 2 of both regimens, indicating lack of eribulin accumulation on subsequent dosing. exploratory analyses: biomarker assessments. Sixty patients (21-day, 34; 28-day, 26) were assessed for biomarker analyses (7 PR, 30 SD, 10 PD, 13 not evaluable). Twenty-one patients (36%) had tumours that tested EGFR FISH-positive (29 negative, 8 undetermined, 2 missing). EGFR protein expression was detected in 46 patients (77%) (6 negative, 8 unknown) . EGFR mutations were detected in 8 patients (13%) (35 wild type, 17 unknown), and KRAS mutations were detected in 15 patients (25%) (30 wild-type, 15 unknown), respectively. Four of the eight patients (50%) with EGFRmutant tumours responded, with DORs of 2.0 (censored), 7.2, 7.4, and 20.4 months. Positive correlations with ORR (P = 0.018) and reduction in tumour volume (P = 0.016) were observed ( Table 2) . No other significant associations were observed between the studied biomarkers and efficacy parameters.
discussion
This randomized phase II study confirmed the feasibility of combining eribulin with erlotinib in an intercalated manner with the 28-day regimen meeting our predefined criteria for a positive result. However, ORRs of 13% and 17% suggest similar efficacy for the two regimens, supported by similar survival outcomes. Our findings suggest that addition of the EGFR-TKI erlotinib does not improve the treatment outcome of eribulin in these patients (no selection by biomarker status) with advanced NSCLC. This may best be explained by the fact that most of the patients in this study did not harbour activating EGFR mutations. When this study was designed, it was unclear whether the intercalated combination of chemotherapy and EGFR-TKI would improve treatment outcomes in patients with or without EGFR mutation. Recent data from NVALT-10 [22] and FASTACT 2 [23] suggest that patients without activating EGFR mutations are unlikely to benefit from the combination. In NVALT-10, intercalated combination of single-agent chemotherapy and erlotinib improved PFS of patients with non-squamous cell carcinoma but not those with squamous cell carcinoma. Although biomarker analysis for EGFR mutation was not available in NVALT-10, it is reasonable to postulate that the majority of patients with squamous cell carcinoma had EGFR mutation-negative tumours. Wu et al. [23] reported similar findings in their randomized phase III study, whereby the benefit of intercalated combination of gemcitabine/platinum and erlotinib was confined to patients with EGFR-mutant tumours. The majority of patients in the current study were white with a history of smoking; only eight (13%) of the tested population had EGFRmutant disease. Thus, our findings also show that addition of EGFR-TKI to chemotherapy fails to improve treatment outcome in patients without EGFR mutation.
Both regimens were generally well tolerated, with no additional safety considerations with the combination. The 21-day regimen was associated with a relatively higher incidence of dose reduction and SAEs. Erlotinib induces cytochrome P450 (CYP)3A4 and decreases exposure (AUC) of co-administered drugs that are CYP3A4 substrates. Eribulin is a CYP3A4 substrate; however, metabolism has been shown to be a minor contribution to eribulin clearance [21] . Prolonged (>7 days) administration of the CYP inducer erlotinib will result in enzyme induction; however, in the current study, eribulin exposure (AUC) and clearance were comparable when eribulin was administered alone (day 1, cycle 1) or after extended administration of erlotinib (day 1, cycle 2). This indicates that CYP3A4 induction does not have a substantial effect on eribulin exposure and that eribulin efficacy will not be compromised when administered with erlotinib according to the dosing regimen tested. These results are in agreement with another study which demonstrated that co-administration with rifampicin, a strong CYP3A4 inducer, also had no effect on eribulin exposure [24] . Given the positive primary result and slightly better tolerance, the 28-day regimen should be considered for future investigation.
The combination of chemotherapy and EGFR-TKI has been controversial. Our study demonstrates the feasibility of combining a novel cytotoxic chemotherapy with EGFR-TKI in an intercalated manner. However, addition of EGFR-TKI is unlikely to improve treatment outcomes in patients without EGFR mutation. Future investigation should explore the combination in patients with EGFR-mutant disease in comparison with single-agent EGFR-TKI.
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